China's Impact Therapeutics oversubscribed 12.3 times in its retail tranche

China's Impact Therapeutics saw its retail tranche oversubscribed 12.3 times in its Hong Kong initial public offering on Tuesday.

It has drawn HK$1.2 billion in margin loans.

The commercial-stage biotechnology company focused on cancer treatment plans to offer 41.98 million H shares, raising at most HK$910 million. Its offer price is between HK$19.75 and HK$21.75 per share. The entry fee for each board lot of 200 shares is HK$4,393.9.

The company is scheduled to debut on May 13.
 

 

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗧𝗵𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗔𝗽𝗽 ↓